Current Report Filing (8-k)
September 27 2021 - 06:06AM
Edgar (US Regulatory)
0001645260 false 0001645260 2021-09-24
2021-09-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, DC
20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported):
September 24, 2021
Todos Medical Ltd.
(Exact name
of registrant as specified in its charter)
|
Israel |
|
000-56026 |
|
n/a |
|
(State or
other jurisdiction |
|
(Commission |
|
IRS
Employer |
|
of
incorporation or organization) |
|
File
Number) |
|
Identification
No.) |
121 Derech Menachem Begin
30th Floor
Tel Aviv,
6701203
Israel
Tel:
(011) (972) 8-633-3964
(Address of
principal executive offices)
Registrant’s
telephone number, including area code: +
972 (52)
642-0126
(Former name
or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communication
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
| |
|
|
☐ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of
each class |
|
Trading
Symbol(s) |
|
Name of
each exchange on which registered |
|
n/a |
|
n/a |
|
n/a
|
Indicate by
check mark whether the registrant is an emerging growth company as
defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
Item 2.02
Results of Operations and Financial Conditions.
On September
24, 2021, Todos Medical Ltd. issued a press release announcing
company highlights and financial results for the second quarter
ended June 30, 2021. A copy of the press release is furnished as
Exhibit 99.1 to this Form 8-K.
The
information disclosed under this Item 2.02, including Exhibit 99.1
hereto, is being furnished and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any
registration statement or other document pursuant to the Securities
Act of 1933, as amended, except as expressly set forth in such
filing.
Item
9.01. Financial Statements and Exhibits
(d)
Exhibits.
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
September 27, 2021
| |
TODOS
MEDICAL LTD. |
|
|
|
|
| |
By: |
/s/
Gerald Commissiong |
| |
|
Gerald
Commissiong |
| |
|
Chief Executive
Officer |
Todos Med (QB) (USOTC:TOMDF)
Historical Stock Chart
From Apr 2022 to May 2022
Todos Med (QB) (USOTC:TOMDF)
Historical Stock Chart
From May 2021 to May 2022
